- Featured Product
- KD/KO Validated
CDK4 Polyclonal antibody
CDK4 Polyclonal Antibody for FC, IF, IHC, IP, WB, ELISA
Cat no : 11026-1-AP
Validation Data Gallery
|Positive WB detected in
|HeLa cells, rat pancreas tissue, HepG2 cells, MCF-7 cells
|Positive IP detected in
|Positive IHC detected in
|human breast cancer tissue, human lung cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in
|Positive FC detected in
|Western Blot (WB)
|WB : 1:1000-1:8000
|IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
|IHC : 1:50-1:500
|IF : 1:50-1:500
|Flow Cytometry (FC)
|FC : 0.20 ug per 10^6 cells in a 100 µl suspension
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
11026-1-AP targets CDK4 in WB, RIP, IP, IHC, IF, FC, CoIP, ELISA applications and shows reactivity with human, rat samples.
|human, mouse, rat, sheep, zebrafish, pig, canine
|Host / Isotype
|Rabbit / IgG
|CDK4 fusion protein Ag1505
|cyclin-dependent kinase 4
|Calculated molecular weight
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
Cyclin-dependent kinase-4 (CDK4) is a protein-serine kinase involved in the cell cycle. It is essential for the G1- to S-phase transition during the cell cycle and its expression is primarily controlled at the transcriptional level(PMID:17253961). CCND1-CDK4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth(PMID:21844184).
|Product Specific Protocols
|WB protocol for CDK4 antibody 11026-1-AP
|IHC protocol for CDK4 antibody 11026-1-AP
|IF protocol for CDK4 antibody 11026-1-AP
|IP protocol for CDK4 antibody 11026-1-AP
|Click here to view our Standard Protocols
METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation.
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC.
CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity.
Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma.
J Pineal Res
Mitochondrial cytochrome P450 (CYP) 1B1 is responsible for melatonin-induced apoptosis in neural cancer cells.
CDK4/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T cell activation in refractory glioblastoma.